Skip to main content
. Author manuscript; available in PMC: 2018 Feb 15.
Published in final edited form as: Biochem Pharmacol. 2016 Oct 24;126:13–22. doi: 10.1016/j.bcp.2016.10.006

Table 1.

Effect of pharmacological modulators of ROS on melanoma cell fate.

20Modulator Model ROS effect Techniques Cell fate Overall conclusion Ref
Nexrutine Melanoma cells &
melanocytes		 Induction H2DCFDA, mitoSOX;
Oxidative stress markers		 Apoptosis ROS, PI3K/mTOR inhibition &
apoptosis induction		 [20]
Benzofuroxan N-Br
& N-I derivatives		 B16F10-Nex2 cells;
syngeneic mouse
model		 Induction Dihydroethidium;
fluorescent microscopy;		 Apoptosis Mitochondrial ROS & reduced
tumor burden		 [29]
Luteolin Melanoma cells Induction H2DCFDA Apoptosis ER stress/ROS with apoptosis [30]
Isoliquiritigenin B16F10 cells Induction H2DCFDA Apoptosis Mitochondrial ROS & apoptosis [31]
DDSD B16F10 cells &
syngeneic mouse
model		 Induction H2DCFDA Apoptosis Mitochondrial apoptosis &
reduced tumor burden		 [32]
4-DACL Melanoma cells,
spheroids, melanocytes		 Induction CellROX Green & Deep
Red Reagent		 Apoptosis Mitochondrial ROS, inhibition
of proliferation and cell cycle		 [33]

4-DACL: (±)-4-deoxyaustrocortilutein; DDSD: (5(R), 19-diacetoxy-15,18(R and S), dihydro spata-13, 16(E)-diene